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Abstract 
Activated lymphocytes have a high level of low density lipoprotein (LDL) uptake as compared to resting lymphocytes, whereas 
scavenger receptors for acetylated LDL (Ac-LDL) are expressed on limited number of immune cells, i.e., monocytes/macrophages. The 
endocytosis of LDL and Ac-LDL by mononuclear cells was studied during in vitro and in vivo HIV infection, in order to use LDL and 
Ac-LDL as carriers of antiviral and/or immunomodulatory d ugs towards lymphocytes and monocytes. The uptake of LDL and Ac-LDL 
was analyzed by cytofluorimetry. LDL endocytosis n PHA/IL2-activated lymphocytes was higher than in resting lymphocytes. In vitro 
HIV infection of PHA/IL2-activated lymphocytes did not alter the high LDL endocytosis n lymphocytes, CD4-- and CD8 ÷ cells. In a 
group of 12 symptomatic patients there was no alteration of LDL endocytosis n lymphocytes, CD4 and CD8 lymphocytes. In another 
group of 23 individuals, the Ac-LDL endocytosis mediated by CDI4 + monocytes was unaltered in asymptomatic patients (n = 6) and in 
some symptomatic patients (n =6, CDI4 ÷ cells > 100/ram3). On the contrary, in other symptomatic patients (n = 11, CD14 ÷ 
cells < 100/mm3), the number of Ac-LDL + CDI4 ÷ cells decreased, whereas their efficiency of Ac-LDL endocytosis increased as 
compared to those of other HIV ÷ patients. In conclusion, the use of lipoproteins as carriers to increase the drug delivery to CD4 + 
lymphocytes and to CDI4 ÷ monocytes can be envisaged, since: (i) the LDL endocytosis was not impaired in CD4 lymphocytes of HIV ÷ 
patients, and (ii) the Ac-LDL uptake by monocytes was altered only in some patients of stage IV. 
Keywords: LDL; CD4 Lymphocyte; Monocyte; HIV 
I. Introduction 
The low density lipoproteins (LDL) are small natural 
vesicles surrounded by a monolayer of phospholipid in 
which a specific protein, apolipoprotein B (apo B), is 
embedded. The LDL deliver cholesterol to the cell through 
endocytosis mediated by the high affinity receptors which 
react with the apo B. Although LDL receptors are found 
on the surface of every cell, their expression differs widely 
and this differential expression can be used as a basis for 
cell targeting. Thus, previous data have shown that cyto- 
toxic compounds incorporated into LDL can be favourably 
delivered to tumour cells by the LDL pathway, since the 
specific endocytosis of LDL increases in numerous tu- 
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mours in vitro and in vivo [1]. On the other hand, high 
affinity LDL receptors are present on lymphocytes [2]. 
Consequently, the LDL pathway might also be used for 
carrying antiviral and/or  immunomodulatory compounds 
to lymphocytes and especially to activated lymphocytes 
that can benefit by the high level of LDL receptor expres- 
sion induced by cell activation. Indeed, it has been demon- 
strated that T lymphocytes activated by Mab CD3 + IL2 
have high LDL receptor expression as compared to resting 
T cells [3]. Such a therapeutic approach could be efficient 
during HIV infection. Indeed, HIV can enter in resting T 
lymphocytes and initiate viral DNA synthesis with the 
same efficiency as in stimulated cells; however, only acti- 
vated lymphocytes can produce virus [4]. Thus, CD4 + 
lymphocytes must be activated to spread viral infection. 
In addition, scavenger receptors for modified LDL have 
been described at the surface of human macrophages but 
not on other immune cells [5]. The scavenger eceptors 
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bind negatively charged lipoproteins and participate in the 
removal of altered lipoproteins from the circulation. Since 
LDL can be easily altered at the apolipoprotein B (apo B) 
site by chemical agents such as acetic acid [6], acetylated 
LDL can be used to carry drugs specifically towards 
monocyte-derived cells. In HIV infection monocytes/mac- 
rophages are a main reservoir of the virus [7,8]. Recently, 
covalent coupling of nucleosides to apo B have been 
performed, and, by altering the apo B, have allowed their 
targeting to mice macrophages in vitro through the scav- 
enger receptor [9]. However, a prerequisite for the use of 
LDL and acetylated LDL (Ac-LDL) to increase the deliv- 
ery efficiency of anti-HIV and/or immunomodulatory 
drugs to immune cells is the knowledge of specific recep- 
tor activities in HIV-infection conditions. The purpose of 
this work was to investigate the activity of LDL receptors 
in lymphocytes and of Ac-LDL receptors in monocytes 
during in vitro and in vivo infection by HIV-I. 
2. Materials and methods 
2. I. Patients 
Total blood was obtained from both HIV-seronegative 
healthy donors (n = 15) and HIV-infected onors (n = 35) 
from the outpatients' department of Purpan hospital (Tou- 
louse, France). HIV-infected patients were classified ac- 
cording to the recommendations of Centers for Disease 
Control (CDC): 6 asymptomatic patients (CDC stages II 
and III), 29 symptomatic patients (CDC stage IV). 
2.2. Isolation, activation and infection of peripheral blood 
mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were iso- 
lated from healthy HIV seronegative donors by centrifuga- 
tion through Ficoll Ipaque (Pharmacia, Guyancourt, 
France). PBMC (2. 10 6 cells/ml) were cultured for 48 h 
with phytohemaglutinin (PHA, 3 /xg/ml; Sigma, La Ver- 
pilli~re, France) in RPMI 1640 medium supplemented with 
Glutamine 2 mM, Fetal Calf Serum 20% (Gibco-BRL, 
Cergy Pontoise, France), Penicillin, Neomycin, Strepto- 
mycin and Interleukin 2 (IL2, 10 I.U./ml). The day of 
infection was defined as Day 0 (DO). After washing, 
PHA-activated PBMC (60. 10 6) were  infected 2 h at 37 ° C 
with 3 ml of supernatant containing HIV-1 BRU (Pasteur, 
Paris, France, TCID 50:1000/ml). The cells were washed 
and cultured in a fresh medium + IL2 (2 • 106 PBMC/ml) 
for several days. No fresh lymphocytes were added to the 
culture, but half the culture medium was changed every 
four days. The control culture consisted of non-infected 
cells of the same donor. The infection progression was 
assessed by evaluating the p24 antigen level by ELISA 
(Abbott, Rungis, France) in the cell-free supernatant and in 
the cell pellet. In long term culture, before each experi- 
ment the cell viability was around 80% as determined by 
the Trypan blue exclusion test. 
2.3. Lipoprotein isolation and labelling with the fluores- 
cent probe Dil 
Low-density lipoproteins (LDL, d = 1.019-- 1.063 
g/ml) were isolated from the plasma of healthy volunteers 
by sequential flotation in KBr (potassium bromide) as 
previously described [ 10]. The concentration of protein in 
LDL was determined by the method of Lowry. LDL was 
labelled with l,l'-dioctadecyl-3,3'tetramethylindocarbo- 
cyanine perchlorate (DiI, Interchim, Montlu~on, France) as 
described [11]. In some experiments, labelled and unla- 
belled lipoproteins were acetylated with repeated addition 
of acetic anhydride [6]. Acetylated LDL were characterized 
by electrophoresis (Tris-Veronal buffer, pH 8.6) in 1% gel 
agarose to evaluate increased migration due to the modifi- 
cation of the whole lipoprotein particle charge [6]. DiI- 
labelled LDL were previously used to study LDL 
receptor-mediated ndocytosis of lymphocytes [3,12], 
whereas DiI-AcLDL were used for studying the Ac-LDL 
uptake by monocytes [12-14]. Fluorescent labelled cells 
can be analyzed by a fluorescence-activated c ll sorter 
(FACS). In addition, FACS allows an easy study of spe- 
cific cell subpopulations after staining by fluorescent mon- 
oclonal antibodies. 
2.4. Uptake of Dil-labelled LDL (DiI-LDL) and of acety- 
lated DiI-labelled LDL (DiI-AcLDL) by infected and unin- 
fected cells 
Routinely, 1 • 10 6 PBMC from infected or non-infected 
cultures taken at different days after infection were incu- 
bated with different concentrations (3 to 50 /xg/ml) of 
DiI-LDL for 5 h at 37 ° C. For experiments done with cells 
of the HIV ÷ patients, total blood was washed twice with 
RPMI - 1% BSA; 200 /zl of blood was then incubated for 
5 h at 37 ° C with 50/xg of DiI-LDL or for 3 h with 10 mg 
of DiI-AcLDL in a final volume of 1 ml of RPMI-I% 
BSA. High-affinity LDL or Ac-LDL uptakes were deter- 
mined with low concentrations of labelled lipoproteins in 
the absence (total uptake) or presence (non-specific up- 
take) of a 20-fold excess of unlabelled LDL or of a 60-fold 
excess of unlabelled Ac-LDL as we have previously de- 
scribed [12]. Cells were then washed at 4 ° C with RPMI- 1% 
BSA. In some experiments (50 /~g/ml of DiI-LDL or 
DiI-AcLDL, 5 h, 37 ° C, n = 3), the total cellular content of 
DiI in freshly CD3 + lymphocytes and in freshly CD14 ÷ 
monocytes of healthy donors was measured using a fluori- 
metric method [15]. The total cellular content of DiI was 
12 ng/mg of proteins in lymphocytes and 160 ng/mg of 
proteins in monocytes, i.e., in term of apo B: respectively, 
240 ng/mg of proteins and 3.2 p~g/mg of proteins. 
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2.5. Immunologic staining of cell suspension 3. Results 
Infected and uninfected cells that internalized labelled 
lipoproteins were stained with anti-CD3, anti-CD4, anti- 
CD8 and anti -CDl4 monoclonal antibodies (MAbs) (2 
/.Lg/106 cells, Immunotech, France) coupled with fluores- 
cein isothiocyanate. In experiments conducted with total 
peripheral blood, the red blood cells were lysed for 5 min 
at room temperature with lysing reagent (Immunotech, 
Marseille, France). Cells were fixed overnight with PBS- 
2% paraformaldehyde, then analysed by a two-colour ana- 
lytical procedure in a cytofluorimeter. 
3.1. Effect of in uitro HIV infection on LDL uptake by 
lymphocytes 
In a first set of experiments the effect of PHA and IL2 
on the LDL uptake by lymphocytes was studied. As shown 
in Fig. 1, IL2 alone cannot efficiently stimulate the LDL 
uptake by lymphocytes, but PHA-activation strongly in- 
creased the LDL endocytosis as compared to PHA-un- 
2.6. Flow cytomet~ analysis 
Analysis was performed either with the Fluorescence- 
activated cell sorter (FACS, Becton Dickinson) or with an 
Epic Elite (Coulter), both equipped with an argon ion 
laser. The laser was operated in the 488 emission wave- 
length. Forward angle and 90 ° light scatter gates were 
established to exclude dead cells and cell debris from 
analysis. Routinely, the lymphocyte and the monocyte 
populations were selected on the basis of cell size, cell 
structure and positivity either to MAb anti-CD3 or to MAb 
anti-CDl4. Fluorescence (>570 nm on the FACS or 
> 575 nm band pass on the Epic Elite) signals from the 
accumulated DiI in the cells were collected by the red 
photomultiplier, converted to digital format and processed 
for storage and display with 256 or 1024 channel resolu- 
tion (FACS and Epic Elite, respectively) in one-parameter 
logarithmic scale frequency histograms. For experiments 
done with cultured cells, five thousand cells were analysed 
for each sample. In experiments conducted with the cells 
of HIV-infected patients, because of the low number of 
monocytes and lymphocytes in some patients, not less than 
20 000 cells were analysed. Autofluorescence of cells incu- 
bated with unlabelled lipoproteins was used as the negative 
control in each experiment. The percentage of cells that 
take up lipoproteins was determined by counting the la- 
belled cells with DiI which exceeded the upper limit of 
autofluorescence of the control cells. The percentage of 
fluorescence positive cells that specifically internalized the 
DiI-lipoproteins was calculated by subtracting the non- 
specific positive cells that take up DiI-lipoproteins in 
presence of an excess of unlabelled lipoproteins (see 
above). Data were also expressed as mean red fluorescence 
intensity (MFI) in arbitrary units (AU). In some experi- 
ments, the specific LDL uptake in the lymphocyte popula- 
tion was expressed as specific total internalization (T1) 
calculated as follows: percentage of specific DiI-positive 
cells × MFI. 
2.7. Statistics 
Statistical analysis of data was carried out using Stu- 
dent's t-test and non-parametric Mann-Whitney U-test. 
P-values were calculated for assessment of significance. 
<~ 
¢- 
O 
100. 
DO 
75- 
50 
25- 
o s'o 
100. 
D2 
75. 
50, 
25. ~ 
o is 5'o 
100- 
D5 
75- 
50., 
25- 
0 
o is go 
DiI-LDL (Dg/mi 
Fig. 1. Effect of cellular activation on LDL endocytosis by lymphocytes. 
PBMC from healthy donors were cultured for 48 h with IL2 (10 
I.U./ml)+PHA (3 /zg/ml) (D), with IL2 (am). After washing (day 0), 
cells were cultured for an additional 5 days in medium with IL2. Aliquots 
of cells were cultured (48 h + washing +5 days) in medium alone ((3). At 
days 0, 2 and 5, 10 6 PBMC were harvested, washed and incubated with 
different concentrations of DiI-LDL for 5 h at 37 ° C. Non-specific 
endocytosis was performed in the presence of 20-fold excess of unla- 
belled LDL. For each sample, 5.103 cells were analysed by flow 
cytometry in lymphocyte area selected as described in Section 2. The 
percentage of LDL positive cells obtained after substraction of non- 
specific LDL positive cells, and their mean fluorescence intensity (MFI) 
in arbitrary units (A.U.) were determined, The total internalisation (TI) 
which represents LDL specific endocytosis in the lymphocyte population 
was calculated as follows: TI = % of DiI-LDL + lymphocytes × MFI. The 
results are the arithmetic mean of the duplicates and are representative of 
two identical experiments. 
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treated cells at days 2 and 5. It appears that PHA/ IL2 -  
treated cells took up LDL about 2- to 3-times more than 
unactivated cells and IL2-treated cells. 
In subsequent experiments, PHA/ IL2-act ivated PBMC 
were infected by HIV-1 BRU, harvested at different days 
and incubated with DiI-LDL. When observed at day 2 after 
infection, lymphocytes took up LDL as efficiently as unin- 
fected cells either in LDL dose-effect  assays or in time-ef- 
fect assays. For example, in one experiment after a 5 h 
incubation with 3 and 50 /xg/ml  of DiI-LDL, 18% and 
70% of lymphocytes of infected culture took up LDL 
(MFI = 0.5 and 0.6 A.U.) versus 20% and 70% of DiI- 
LDL + lympbocytes (MFI = 0.5 and 0.7 A.U.) in control 
culture. Similarly, after 0.5, 1, 2, 4 and 5 hours of incuba- 
tion with 50 /xg/ml  DiI-LDL, 12, 26, 33, 55 and 64% of 
lymphocytes of infected culture took up LDL (MFI = 0.5 
to 0.6 A.U.) versus 13, 25, 35, 57 and 60% of Di I -LDL + 
lymphocytes (MFI = 0.5 to 0.6 A.U.) in control culture. 
According to the day of culture, the LDL total internaliza- 
tion (TI) in lymphocytes of infected cultures was similar to 
that of non-infected cultures (Fig. 2A). Thus, HIV infec- 
tion does not disturb the DiI-LDL total endocytosis medi- 
ated by the PHA/ IL2-act ivated lymphocyte population. 
Results of a dual immunofluorescence analysis showed 
that the same percentage of CD4 + and CD8 + cells were 
able to take up Di I -LDL in each T-lymphocyte population 
(Fig. 2B). Identical results were observed in long-time 
cultures (18 days). Viral infection was controlled by deter- 
mining the level of p24 antigen concentration i the super- 
natant of culture: p24 antigen increased steadily from day 
0 to day 18 (Fig. 3A). As expected, since CD4 + cells 
represent the main target cell of HIV infection [16], CD4 + 
lymphocyte percentage decreased as viral antigen concen- 
tration increased (Fig. 3B). The specific LDL uptake by 
lymphocytes, expressed as TI, was determined at different 
days after infection. The ratio of TI in lymphocytes of 
infected cul ture/T I  in lymphocytes of non-infected culture 
was then calculated. As shown in Fig. 3 C, this ratio is 
around 1. A dual immunofluorescence analysis showed 
that CD4 + and CD8 + cells from infected culture take up 
LDL as efficiently as cells from control culture since the 
MFI of DiI-positive cells is identical in infected and 
uninfected culture (Fig. 3D and E). The same results were 
observed when the results were expressed as percent of 
Di I-LDL + cells in each T-cell populations (not shown). 
These results indicate that whatever the progression of in 
vitro HIV infection and the CD4 cell number, the ability of 
PHA/ IL2  activated lymphocytes to endocytose LDL is 
unaltered by HIV. 
3.2. LDL uptake by lymphocytes of  HIV-I infected patients 
LDL endocytosis by lymphocytes was studied in in- 
fected patients of stage IV (n - :  12). The high specific 
Di I -LDL uptake was assessed in the total lymphocyte 
population and in CD4 ÷ or CD8 ÷ lymphocyte subpopula- 
tions. Fig. 4 shows that total lymphocytes, CD4 ÷ and 
CD8 ÷ lymphocytes of HIV-1 infected patients endocy- 
tosed LDL as efficiently as lymphocytes of non-infected 
subjects. Then, the previous HIV ÷ patients were separated 
into two groups depending on the usual limit of 200 CD4 ÷ 
ce l l s /mm 3(< 200 CD4 + ce l l s /mm 3, n = 8; > 200 CD4 + 
ce l l s /mm 3, n = 4). When results were expressed as per- 
cent of Di I -LDL ÷ cells and as MFI in each T-cell subpop- 
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Fig. 2. Effects of in vitro HIV infection on LDL endocytosis by lympho- 
cytes in short-term culture. PMBC were activated with PHA + IL2 for 48 
h. Cells were washed and infected (11) or not (13) with HIV-I at day 0, 
then cultured for 7 days in a medium containing IL2. (A) At different 
days after infection, 10 6 cells were collected, washed and incubated with 
different concentrations of DiI-LDL for 5 h at 37 ° C. Non-specific 
endocytosis was performed in the presence of 20-fold excess of unla- 
belled LDL. Simple histogram analysis was performed in lymphocyte 
area to determine the percentage of DiI-LDL + cells. Results are ex- 
pressed as total specific internalization f DiI-LDL in lymphocyte popula- 
tion from day 0 (DO) to day 7 (D7). (B) At different days after infection, 
cells were incubated for 5 h with 50 ,o,g of DiI-LDL, then stained with 
anti-CD4 and anti-CD8 MAbs. A dual fluorescence analysis was assessed 
to determine the percentage of LDL + CD4 + or LDL + CD8 ÷ cells• The 
figures represent the % of LDL + CD4 + in CD4 + lymphocyte population 
(B Top) and the % of LDL ÷ CD8 + in CD8 + lymphocyte population (B 
Bottom) after substraction of non-specific DiI-LDL endocytosis. The 
results hown in A and B are mean ! S.D, of 3 independent experiments. 
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ulation, LDL endocytosis was similar in the both groups of 
HIV ÷ donors (not shown). 
3.3. Modified LDL uptake by monocytes of HIV-1 infected 
pat ients  
The activity of Ac-LDL receptors on the monocyte 
surface of HIV-1 infected patients was studied through 
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Fig. 3. Effects of in vitro HIV infection on LDL endocytosis by lympho- 
cytes in long-term culture. Activated PBMC were infected (day 0) with 
HIV-1, washed and cultured for 18 days in a medium containing IL2. At 
different days after infection, aliquots of cells were harvested and stained 
with MAb anti-CIM. Other aliquots were incubated with 50 p,g of 
DiI-LDL for 5 h at 37 ° C. Non-specific endocytosis was performed in the 
presence of 20-fold excess of unlabelled LDL. Then for each sample 
incubated with lipoproteins, cells were stained with anti-CD4 and anti- 
CD8 MAbs. A simple histogram and a dual fluorescence analysis were 
performed. Viral infection was assessed by ELISA for determination f
p24 viral antigen concentration i  the supernatant of culture. Percentage 
of specific LDL + lymphocytes of infected and non-infected cultures and 
their MFI was determined. From the top to the bottom: (A) p24 antigen 
concentration (ng/ml) assessed by ELISA test at different days after 
infection, (B) percent of CD4 + cells in infected culture, (C) LDL-specific 
total internalization (TI) in lymphocytes of infected culture/LDL TI in 
lymphocytes of non-infected culture, (D) and (E) MFI in arbitrary units of 
LDL + cells in CIM ÷ and CD8 + lymphocyte populations of infected 
(11) or non-infected culture (1:3). Results are representative of two 
identical experiments. 
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Fig. 4. LDL endocytosis by lymphocytes of HIV infected patients. 
Washed samples of 200/~l of blood from 12 HIV + patients, classified in 
stage IV according to the CDC classification, were incubated with 50/zg 
of DiI-LDL for 5 h at 37 ° C. Non-specific endocytosis was performed in 
the presence of a 20-fold excess of unlabelled LDL. Aliquots of each 
sample incubated with lipoprotein were stained with anti-CIM MAb and 
anti-CD8 MAb conjugated with FITC. Red cells were lysed, then a 
simple histogram analysis and a dual fluorescence analysis were per- 
formed. Results represent LDL endocytosis expressed as mean fluores- 
cence intensity (MFI) + S.E.M., in total lymphocytes (Total), CIM + and 
CD8 + lymphocytes of HIV-I infected patients, n = 12 ( l l )  or non-in- 
fected controls, n = 5 ( [] ). 
experiments of AcLDL endocytosis. As for LDL uptake, 
competitive assays with unlabelled Ac-LDL were done to 
determine high specific Ac-LDL uptake. Firstly, Ac-LDL 
endocytosis by monocytes from blood of healthy donors 
was compared to that of lymphocytes from the same 
donors. After a 5 h incubation of cells with 50 ~g/ml  of 
DiI-AcLDL, a dual fluorescence analysis of DiI-AcLDL 
endocytosis by freshly isolated CD14 ÷ monocytes or 
freshly isolated CD3 + lymphocytes was performed. As 
expected, CD14 ÷ monocytes have a high AcLDL endocy- 
Table 1 
Ac-LDL uptake by monocytes from HIV-infected patients 
Patients Percentage MFI 
Controls (n = 10) 85 :i: 12 6.5 +_ 2.3 
Asymptomatics (n = 6) 83_ 10 5.2 +_ 3.3 
Symptomatics a (n = 6) 81 + 7 4.6__+ 2.0 
Symptomatics b (n = 11) 66+21 * 8,9_+2.1 * ,o,o 
Washed blood samples were incubated with 10 /xg of Ac-LDL for 3 h at 
37 ° C. Non-specific endocytosis was performed in the presence of a 
60-fold excess of unlabelled Ac-LDL. After staining by anti-CD14 MAb, 
red cells were lysed and Ac-LDL uptake by CD14 + monocytes was 
assessed by flow cytometry. The results (mean+S.D.) are expressed as 
percentage of DiI-AcLDL positive cells after subtraction of non-specific 
endocytosis and as MFI in A.U. Controls were HIV seronegative h althy 
donors (n = i0). HIV + infected patients (n = 23) were classified accord- 
ing to their clinical stage as defined by the CDC: asymptomatic HIV + 
patients (stage II and III) and symptomatic HIV + patients (stage IV). In 
symptomatic patients, two groups were formed according to their CD14 + 
count/mm3: a CDI4 > 100, n = 6; b CD14 < 100, n = 11. * P < 0.05 as 
compared to the controls, ©P < 0.05 as compared to asymptomatic 
HIV + patients, O p < 0.01 as compared to symptomatic patients of 
group a (Student's t-test; in each case, the significance of the differences 
was confirmed by Mann-Whitney U-test). 
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Fig. 5. Dot plots of dual-colour immunofluorescence of DiI-AcLDL endocytosis by CD 14 + monocytes or CD3 + lymphocytes. Total blood from healthy 
donors was washed and 200 /~1 of blood were incubated with 50 /~g/ml DiI-AcLDL for 5 h at 37 ° C. Cells were then washed and stained by MAb 
anti-CD14 or MAb anti-CD3 conjugated with fluorescein (FITC). Red cells were lysed and the remaining cells were washed twice and fixed. The figure 
shows the results obtained from one donor. CD14 + monocytes analysis: cells were gated in an area containing monocytes and lymphocytes. However, the 
same results were obtained when cells gated only in the monocyte area were analysed. DiI-AcLDL endocytosis by freshly isolated CD14 ÷ monocytes in 
the absence (A) or in the presence of 600 /xg/ml unlabelled Ac-LDL (B). (C) DiI-AcLDL endocytosis n the absence of unlabelled Ac-LDL by CD3 ÷ 
lymphocytes gated in lymphocyte area. For each dot plot, quadrant 1 represents DiI staining only, quadrant 2 is dual staining, quadrant 4 is fluorescein 
staining. The unstained cells are in quadrant 3. Same dot-plots were obtained for DiI-AcLDL by CDI4 ÷ monocytes from HlV-infected patients. 
tosis (Fig. 5A) as compared to CD3 ÷ lymphocytes (Fig. 
5C). Competition assays showed that DiI-AcLDL endocy- 
tosis by CD14 ÷ monocytes, mediated by scavenger recep- 
tor, is strongly inhibited by an excess of unlabelled AcLDL 
(Fig. 5B). Experiments of dose and time effects with blood 
of healthy subjects were then performed and showed satu- 
rated AcLDL endocytosis at concentrations a  low as 10 
/xg/ml and for 3 h incubation time (results not shown). 
Finally, these later conditions were used to study AcLDL 
endocytosis by monocytes of infected patients. The study 
of the DiI-AcLDL endocytose, xpressed as MFI and % of 
fluorescence positive cells, in CD14 ÷ monocytes of HIV-1 
infected patients (n = 23) and non-infected controls (n = 
10) showed no difference (results not shown). In the same 
way, when infected patients were divided into two groups 
according to the limit number of 200 CD4 ÷ 
lymphocytes/mm 3, there was no difference as compared 
to healthy donors or between the infected patients them- 
selves. However, 10/14 patients with less than 200 
CD4/mm 3 had a number of CD14 + monocytes <
100/mm 3 versus only 2 /9  in patients with more than 200 
CD4 ÷ cel ls/mm 3. Consequently, HIV ÷ patient dispatch- 
ing was done depending on this arbitrary low limit of 
CD14 ÷ monocyte number. Under these circumstances, in 
patients with less than 100 CD14 + cel ls /mm 3 (n = 12) 
the AcLDL ÷ CD14 ÷ cell percentage (mean_ S.D.) was 
decreased (66 +_ 19%), whereas their MFI was increased 
(8.6-t-2.2%) as compared to controls (respectively 85 + 
12%, P < 0.02 and 6.5 _ 2.3%, P < 0.05) and to the other 
group of HIV ÷ patients (83 +__ 8%, P < 0.02 and 4.9 ± 
2.7%, P < 0.005). Infected patients were also divided into 
two groups according to disease expression (Table 1): 
asymptomatic patients and symptomatic patients. Asymp- 
tomatic patients (n = 6) had the same Ac-LDL endocytosis 
as controls, whereas ymptomatic patients howed moder- 
ate decrease of the Ac-LDL ÷ cell percentage (P < 0.02 in 
patients with CD14 ÷ number < 100from 3, as shown in 
Table 1). Finally, the association of clinical and immuno- 
logical characteristics onfirmed that, in symptomatic pa- 
tients, a low number of CD14 monocytes/mm 3 (< 100) is 
associated with an increase of the AcLDL uptake effi- 
ciency (in MFI) by some of these monocytes (Table 1). 
4. Discussion 
In this work the effects of HIV-I infection on the LDL 
and Ac-LDL endocytosis by lymphocytes and monocytes 
were studied. Once a DiI-labelled lipoprotein has been 
internalized by cells, lysosomal enzymes degrade the 
lipoprotein molecules and DiI accumulates in the mem- 
branes. Cells that metabolize lipoproteins at different rates 
will accumulate varying amounts of DiI and will display 
different fluorescences. Thus, the increase of fluorescence 
in PHA/IL2-activated cells as compared to inactivated 
cells confirms that LDL receptor activity is enhanced by 
lymphocyte activation and proliferation as previously 
shown by the use of anti-CD3 MAb + IL2 [3]. 
Impairment of lymphocyte functions is one of the main 
characteristics of HIV-1 infection [17]. In in vitro experi- 
ments of short-term and long-term culture, we have found 
that total lymphocytes, CD4 ÷ and CD8 ÷ lymphocytes, 
activated by PHA/ IL2 and harvested from HIV-infected 
cultures, endocytosed LDL as efficiently as lymphocytes 
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from uninfected cultures. Although the level of LDL endo- 
cytosis directly performed by the HIV-infected CD4 + 
lymphocytes was not demonstrated, results show that, in 
infected cultures, the LDL endocytosis by the CD4 + lym- 
phocyte subpopulation, containing the main HIV-target 
cells and in activation conditions, is not impaired. In 
experiments with HIV-1 infected patients, a rapid tech- 
nique was developed to study LDL or Ac-LDL endocytose 
by either lymphocytes or monocytes using total peripheral 
blood. As observed in in vitro infection experiments, in
vivo infection does not modify the effectiveness of LDL 
endocytosis by either total peripheral lymphocytes orCD4 + 
and CD8 + lymphocytes. Although we have not directly 
studied the LDL receptor activity in lymphocytes which 
were both HIV-infected and activated in vivo, taken to- 
gether our in vivo and in vitro results suggest hat a high 
LDL endocytosis can exist in activated CD4 lymphocytes 
during HIV infection. 
Monocytes have important immunoregulatory functions 
that can be compromised by HIV infection and pathologi- 
cal changes in monocytes can contribute to the impairment 
of the immune system [18]. However, a lot of clinical 
studies show little or no change in blood monocyte num- 
ber, phenotype or functions throughout H1V infection [19]. 
In the same way, our results indicate that Ac-LDL endocy- 
tosis is unaltered in asymptomatic HIV-infected patients. 
However, the efficiency of Ac-LDL endocytosis clearly 
increases in some monocytes, from the asymptomatic pa- 
tients to the symptomatic patients characterized by a high 
immunological perturbation, suggesting that a progressive 
change in cell metabolism appears during the infection 
(Table 1). It is unlikely that this increase of AcLDL 
endocytosis can be due only to the change of HIV-infected 
monocyte number. Indeed, there is an exceedingly low 
frequency of infected monocytes in circulation (< 0.01% 
of total monocytes [19]). However, the development of 
H1V infection can alter some functions of uninfected 
monocytes. Thus, clinical studies have shown a correlation 
between the disease stage and the capacity of blood mono- 
cytes to produce IFN [19], and recent reports have indi- 
cated that HIV glycoproteins, e.g. gpl20, can modulate the 
monocyte secretory function [20]. In the same way, there 
might be a correlation between the alteration of Ac-LDL 
endocytosis and the stage of disease. 
Over the last l0 years, LDL have been examined 
experimentally as drug-delivery vehicle [21,22]. Thus, the 
use of LDL as a carrier of drugs in cancer therapy is well 
documented [1,23]. Some advantages of the delivery by 
using LDL and modified LDL could be: (i) an increase in 
the half-life (2 to 3 days for LDL) of the drug and the 
targeting towards the cells characterized by high LDL 
requirements, (ii) a decrease in the risk of inducing im- 
mune response to the drug and of its damage by extracellu- 
lar enzymes, (iii) an easier diffusion from the vascular to 
the extravascular compartment, (iv) an intraceilular uptake 
of drug via a receptor-mediated endocytosis allowing the 
bypass of drug resistance mechanisms atthe cell level. The 
main disadvantage of LDL is a lack of targeting, since 
receptors are expressed on numerous tissues. Thus, the 
liver takes up about 2 /3  of blood LDL. However, as 
shown in vivo in human cancer, administration of bile 
acids down-regulates LDL-receptor activity in the liver 
and increases the targeting towards the tumour [23]. A 
second disadvantage of LDL as drug delivery system, is 
their ability to entrap only lipophilic drugs, most drugs 
used in therapeutics being hydrophilic. However, new drug 
delivery systems were recently built to mimic LDL and to 
allow entrapment of hydrophilic drugs [24]. Finally, nu- 
merous works have shown the feasibility of preparation of 
antitumour drug-LDL complexes and the efficiency of 
their delivery to the tumour with high uptake of LDL 
[1,23]. Similarly, since lymphocyte proliferation and acti- 
vation strongly increase LDL uptake in spite of HIV 
infection, and since HIV replication is strictly dependent 
on cell activation [25,26], it is reasonable to suggest that a 
significant argeting of anti-HIV drugs by means of LDL 
receptor to activated lymphocytes can be obtained. 
The apoprotein of LDL can be modified to allow recog- 
nition by receptors other than the physiological LDL re- 
ceptors: e.g., lactosylated LDL allow drug-targeting to 
Kuppfer cells by galactose-specific receptors [27]. Unlike 
LDL, the acetylated LDL allows specific targeting to 
monocytes/macrophages, since they are the only immune 
cells endocyting acetylated LDL via the scavenger recep- 
tors with a very high efficiency [28]. However, the acety- 
lated LDL is removed from the circulation by the sinu- 
soidal endothelial cells of the liver, spleen, bone marrow, 
adrenal and ovary glands. The other endothelial cells (of 
arteries, veins, or capillaries of the heart, testes, kidney, 
brain, adipose tissue, and duodenum) did not endocytose 
Ac-LDL [29]. The specific uptake of AcLDL by sinusoidal 
endothelia could reflect he requirement for cholesterol: in 
the ovary and adrenal glands for hormone production, in 
the spleen and bone marrow for blood cell membrane, and 
in the liver for bile production [29]. One has to assume 
that, in vivo, administration of bile acids could decrease 
the requirement of cholesterol, therefore the clearance of 
Ac-LDL by the liver endothelial cells. However, this limi- 
tation for targeting drugs to monocytes/macrophages, can 
be an advantage if the drug is released from endothelial 
cells to the liver, spleen and bone marrow cells that 
contain putative target macrophages for HIV. In addition, 
since it was recently shown that human liver endothelial 
cells are potential target cells for HIV and can play a role 
in the pathophysiology of AIDS [30], it can be proposed to 
use Ac-LDL for anti-HIV drug targeting to these cells. 
Concerning monocytes/macrophages, theyare described 
as susceptible targets, persistent reservoirs for HIV and 
key immunoregulatory elements that control the extent of 
disease [31]. On the other hand, it has been described that 
efficient viral replication in monocytes or macrophages 
depends on both cell activation and differentiation [32], 
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known to increase the number of scavenger receptors for 
acetylated LDL at the cell surface [33,34]. Consequently, 
the use of the acetylated LDL receptor-mediated en ocyto- 
sis for anti-HIV drug-targeting appears attractive. Finally, 
if the increase of acetylated LDL endocytosis in some 
CDI4 monocytes reflects functional abnormalities of 
monocytes/macrophages in later stages of the disease, it is 
propitious to use acetylated LDL to carry drugs to these 
cells to restore or stimulate their functions. 
In conclusion, this work leads to the consideration of 
LDL and acetylated LDL as potential candidates to carry 
anti-HIV drugs towards immune cells during AIDS. 
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